The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Korobka V.L.

FGBOU VO «Rostovskij gosudarstvennyj meditsinskij universitet» Minzdrava Rossii, Rostov-na-Donu

Pak E.S.

Rostov Regional Clinical Hospital, Rostov Region, Rostov-on-Don, Russia;
Rostov State Medical University, Ministry of Health of the Russia, Rostov-on-Don, Russia

Pasechnikov V.D.

Kostrykin M.Yu.

Rostov Regional Clinical Hospital, Rostov Region, Rostov-on-Don, Russia

Compensation of HCV-associated decompensated cirrhosis treated with modern direct-acting antiviral agents

Authors:

Korobka V.L., Pak E.S., Pasechnikov V.D., Kostrykin M.Yu.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2019;8(4): 11‑21

DOI: 10.17116/dokgastro2019804-05111

Read: 5022 times

Download PDF (RU)
Contact the author
Table of contents

COMPENSATION OF HCV-ASSOCIATED DECOMPENSATED CIRRHOSIS TREATED WITH MODERN DIRECT-ACTING ANTIVIRAL AGENTS
COMPENSATION OF HCV-ASSOCIATED DECOMPENSATED CIRRHOSIS TREATED WITH MODERN DIRECT-ACTING ANTIVIRAL AGENTS

To cite this article:

Korobka VL, Pak ES, Pasechnikov VD, Kostrykin MYu. Compensation of HCV-associated decompensated cirrhosis treated with modern direct-acting antiviral agents. Russian Journal of Evidence-Based Gastroenterology. 2019;8(4):11‑21. (In Russ.)
https://doi.org/10.17116/dokgastro2019804-05111

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Aim. To assess the efficacy of the direct-acting antiviral agents (DAA) in patients with decompensated HCV-associated liver cirrhosis. Material and methods. A retrospective case-control study was conducted. Case cohort enrolled ten adults with HCV-associated decompensated liver cirrhosis included in the waiting list for liver transplantation. These patients were delisted after DAA therapy due to recompensation of liver cirrhosis. Control cohort comprised of 32 patients with HCV–associated decompensated liver cirrhosis included in the waiting list for the same period. Subcompensation of liver cirrhosis developed in these patients. Results. Administration of DAA (combination of sofosbuvir, daclatasvir and ribavirin) for 12 and 24 weeks (in patients with contraindications for ribavirin) resulted in a sustained virologic response in 100% cases in both cohorts. Antiviral therapy significantly reduced MELD and Child—Turcotte—Pugh values in patients with recompensation of liver cirrhosis. Moreover, significant decrease of the international normalized ratio, blood bilirubin, alkaline phosphatase, Na, improvement of platelet and leukocyte levels were observed in this cohort of patients. Conclusion. The study showed the possibility of recompensation of HCV-associated liver cirrhosis after DAA administration. Antiviral therapy significantly reduced MELD and Child—Turcotte—Pugh values and improved liver function tests.

Keywords:

liver transplantation
waiting list
delisting due to recompensation of liver cirrhosis
direct-acting antiviral agents
stable virologic response

Authors:

Korobka V.L.

FGBOU VO «Rostovskij gosudarstvennyj meditsinskij universitet» Minzdrava Rossii, Rostov-na-Donu

Pak E.S.

Rostov Regional Clinical Hospital, Rostov Region, Rostov-on-Don, Russia;
Rostov State Medical University, Ministry of Health of the Russia, Rostov-on-Don, Russia

Pasechnikov V.D.

Kostrykin M.Yu.

Rostov Regional Clinical Hospital, Rostov Region, Rostov-on-Don, Russia

Close metadata

References:

  1. 1. Adam R, Karam V, Cailliez V, O Grady JG, Mirza D, Cherqui D, Klempnauer J, Salizzoni M, Pratschke J, Jamieson N, Hidalgo E, Paul A, Andujar RL, Lerut J, Fisher L, Boudjema K, Fondevila C, Soubrane O, Bachellier P, Pinna AD, Berlakovich G, Bennet W, Pinzani M, Schemmer P, Zieniewicz K, Romero CJ, De Simone P, Ericzon BG, Schneeberger S, Wigmore SJ, Prous JF, Colledan M, Porte RJ, Yilmaz S, Azoulay D, Pirenne J, Line PD, Trunecka P, Navarro F, Lopez AV, De Carlis L, Pena SR, Kochs E, Duvoux C; all the other 126 contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Annual Report of the European Liver Transplant Registry (ELTR) — 50-year evolution of liver transplantation. Transplant International. 2018;31:1293-1317. https://doi.org/10.1111/tri.13358
  2. Berenguer M, de la Rosa Rodríguez G, Domínguez-Gil B. Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain. Journal of Hepatology. 2018;69(4):966-968. https://doi.org/10.1016/j.jhep.2018.06.011
  3. Scognamiglio P, Piselli P, Fusco M, Isanti FA, Serraino D, Ippolito G, Girardi E; Collaborating Study Group. Declining unawareness of HCV-infection parallel to declining prevalence in Southern Italy. Journal of Medical Virology. 2017;89(10):1691-1692. https://doi.org/10.1002/jmv.24840
  4. Angelico M, Cillo U, Fagiuoli S Gasbarrini A, Gavrila C, Marianelli T, Costa AN, Nardi A, Strazzabosco M, Burra P, Agnes S, Baccarani U, Calise F, Colledan M, Cuomo O, De Carlis L, Donataccio M, Ettorre GM, Gerunda GE, Gridelli B, Lupo L, Mazzaferro V, Pinna A, Risaliti A, Salizzoni M, Tisone G, Valente U, Rossi G, Rossi M, Zamboni F. Liver Match Investigators. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donorrecipient matching. Digestive and Liver Disease. 2011;43(2):155-164.
  5. Gautier SV, Khomyakov SM. Donation and organ transplantation in the Russian Federation in 2018. 11th report of National Register. Vestnik transplantologii i iskusstvennykh organov. 2019;21(3):7-32. (In Russ.)
  6. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WTH, MacDonald DC, Agarwal K, Foster GR, Irving WL. HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology. 2016;65(4):741-747. https://doi.org/10.1016/j.jhep.2016.06.019
  7. Terrault NA, McCaughan GW, Curry MP Gane E, Fagiuoli S, Fung JYY, Agarwal K, Lilly L, Strasser SI, Brown KA, Gadano A, Kwo PY, Burra P, Samuel D, Charlton M, Pessoa MG, Berenguer M. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017;101(5):945-955. https://doi.org/10.1097/TP.0000000000001708
  8. D’Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct acting antivirals: the endgame for hepatitis C? Current Opinion in Virology. 2017;24:31-37. https://doi.org/10.1016/j.coviro.2017.03.017
  9. Fernández Carrillo C, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J, Fernández I, Baliellas C, Carrión JA, de la Mata M, Buti M, Castells L, Albillos A, Romero M, Turnes J, Pons C, Moreno-Planas JM, Moreno-Palomares JJ, Fernández-Rodriguez C, García-Samaniego J, Prieto M, Fernández Bermejo M, Salmerón J, Badia E, Salcedo M, Herrero JI, Granados R, Blé M, Mariño Z, Calleja JL. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. Hepatology. 2017;65(6):1810-1822. https://doi.org/10.1002/hep.29097
  10. Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, Roberts MS, Terrault N, Chung RT. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology. 2018;67(6):2085-2095. https://doi.org/10.1002/hep.29723
  11. Vinaixa C, Strasser SI, Berenguer M. Disease Reversibility in Patients with Post-Hepatitis C Cirrhosis: Is the Point of no Return the Same before and after Liver Transplantation? A Review. Transplantation. 2017;101(5):916-923. https://doi.org/10.1097/TP.0000000000001633
  12. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology. 2016;64(6):1224-1231. https://doi.org/10.1016/j.jhep.2016.01.029
  13. Afdhal N, Everson GT, Calleja JL, McCaughan G, Bosch J, Denning J, Brainard DM, McHutchison JG, Brandt-Sarif T, An D, Charlton M, Reddy Rajender, Asselah, T,Gane E, Forns X. Effect of Long-Term Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension. 2015 International Liver Congress: 50th Annual Meeting of the European Association of the Study of the Liver (EASL). 2015; Abstract LP13.
  14. Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, Cammà C, Grimaudo S, Pipitone RM, Simone F, Peralta S, Arini A, Craxì A. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology. 2016;151(1):130-139. https://doi.org/10.1053/j.gastro.2016.03.036
  15. Sáez-González E, Vinaixa C, San Juan F, Hontangas V, Benlloch S, Aguilera V, Rubín A, García M, Prieto M, López-Andujar R, Berenguer M. Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). Liver International. 2018;38(6):1022-1027. https://doi.org/10.1111/liv.13618
  16. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C; European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal of Hepatology. 2016;65(3):524-531. https://doi.org/10.1016/j.jhep.2016.05.010
  17. Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, Charlton M. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017;152(5):1090-1099. https://doi.org/10.1053/j.gastro.2017.01.003
  18. Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65(3):804-812. https://doi.org/10.1002/hep.28923
  19. Aravinthan AD, Barbas AS, Doyle AC, Tazari M, Sapisochin G, Cattral MS, Ghanekar A, McGilvray ID, Selzner M, Greig PD, Bhat M, Selzner N, Grant DR, Lilly LB, Renner EL. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. Transplant International. 2017;30(3):1140-1149. https://doi.org/10.1111/tri.13008
  20. Wiesner R, Lake JR, Freeman RB, Gish RG. Model for end-stage liver disease (MELD) exception guidelines. Liver Transplantation. 2006;12(12 Suppl 3):S85-S87. https://doi.org/10.1002/lt.20979
  21. Leise MD, Kim WR, Kremers WK, Larson JJ, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology. 2011;140(7):1952-1960. https://doi.org/10.1053/j.gastro.2011.02.017
  22. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735. https://doi.org/10.1002/hep.27210
  23. Volk ML, Hernandez JC, Lok AS, Marrero JA. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transplantation. 2007;13(11):1515-1520. https://doi.org/10.1002/lt.21172
  24. Korobka VL, Shapovalov AM, Danil’chuk OYa, Korobka RV. Sposob khirurgicheskogo lecheniya i profilaktiki retsidiva krovotechenij pri varikoznom rasshirenii ven pishchevoda i kardial’nogo otdela zheludka. Patent RF №2412657/23.07.2009. Accsessed November 06, 2019. (In Russ.) Available at: http://www.freepatent.ru/images/patents/48/2412657/patent-2412657.pdf
  25. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology. 2018;69(2):461-511. https://doi.org/10.1016/j.jhep.2018.03.026
  26. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. Journal of Hepatology. 2017;66(1):153-194. https://doi.org/10.1016/j.jhep.2016.09.001
  27. Bakulin I, Pasechnikov V, Varlamicheva A, Sannikova I. NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. World Journal of Hepatology. 2014;6(5):326-339. https://doi.org/10.4254/wjh.v6.i5.326
  28. Perricone G, Duvoux C, Berenguer M, Cortesi PA Cortesi PA, Vinaixa C, Facchetti R, Mazzarelli C, Rockenschaub SR, Martini S, Morelli C, Monico S, Volpes R, Pageaux GP, Fagiuoli S, Belli LS. European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting. Liver International. 2018;38(12):2170-2177. https://doi.org/10.1111/liv.13878
  29. Coilly A, Pageaux GP, Houssel-Debry P, Duvoux C, Radenne S, de Ledinghen V, Botta D, Vallet-Pichard A, Anty R. Di Martino V, Conti F, Debette M, Gratien M, Alric L, Abergel A, Besch C, Montialoux H, Lebray S, Dharancy S, Durand F, D’Alteroche L, Charier F, Chazouilleres O, Dumortier J, Leroy V, Duclos-Vallee DC. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAAs? Hepatology. 2015;62:257A.
  30. Pascasio JM, Vinaixa C, Ferrer MT Colmenero J, Rubin A, Castells L, Manzano ML, Lorente S, Testillano M, Xiol X, Molina E, González-Diéguez L, Otón E, Pascual S, Santos B, Herrero JI, Salcedo M, Montero JL, Sánchez-Antolín G, Narváez I, Nogueras F, Giráldez Á, Prieto M, Forns X, Londoño MC. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. Journal of Hepatology. 2017;67(6):1168-1176. https://doi.org/10.1016/j.jhep.2017.08.008
  31. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49(3):729-738. https://doi.org/10.1002/hep.22694
  32. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, Pol S. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Annals of Internal Medicine. 2008;149(6):399-403. https://doi.org/10.7326/0003-4819-149-6-200809160-00006
  33. Roberts S, Gordon A, McLean C, Pedersen J, Bowden S, Thomson K, Angus P. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clincal of Gastroenterology and Hepatology. 2007;5(8):932-937. https://doi.org/10.1016/j.cgh.2007.02.022
  34. Macken L, Gelson W, Priest M, Abouda G, Barclay S, Fraser A, Healy B, Irving W, Verma S. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort. Journal of Medical Virology. 2019;91(11):1979-1988. https://doi.org/10.1002/jmv.25552
  35. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O’Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N; SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649-659. https://doi.org/10.1053/j.gastro.2015.05.010
  36. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X, SOLAR-2 Investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. The Lancet. Infectious Diseases. 2016;16(6):685-697. https://doi.org/10.1016/S1473-3099(16)00052-9
  37. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493-1505. https://doi.org/10.1002/hep.28446
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.